| Name | Title | Contact Details |
|---|
Rooted in Relationships, Backed by Results. Our Mission is to revolutionize the perception and impact of employee well-being by creating and proving the correlation of employee well-being with bottom line revenue. To help medium and large-sized organizations by deploying and managing tailored programs that are customized for every client and personalized for each participant. To deliver total Return on Well-being for every client, including individual health improvement, heightened employee engagement, increased productivity, cultural improvement, lower healthcare costs, and higher profitability. Our Vision is to revolutionize the way corporate America values employee well-being by correlating improved employee health and employee engagement with decreased human resources costs and improved financial performance. Our Purpose is to impact our clients’ success and the quality of life of each individual we touch. Through Guaranteed Support; Guaranteed Enjoyment; Guaranteed Improvement you’ll see how we can impact your Return on Well-being (ROW) and improve the health and well-being of your workforce. Connect with us to start the change!
MPTF is unique as a national model of integrated health and human services and that there is no other such organization dedicated to taking care of a single industry. MPTF has six health centers located in Southern California.
Soka Services LLC is a Pontiac, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. have entered a global collaboration and licensing agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer. Apatorsen is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development.
Archimedes, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.